GTC Biotherapeutics will collaborate with Ovation

GTC Biotherapeutics Inc. of Framingham and Ovation Pharmaceuticals Inc. said today that they have entered into a collaboration agreement to develop and market a drug treatment called ATryn in the United States.

ATryn is GTC’s recombinant form of human antithrombin, a plasma protein with anticoagulant and anti-inflammatory properties, and the collaboration includes development and commercialization of ATryn in the hereditary antithrombin deficiency, or HD, indication, the companies said in a press release.

The agreement includes $257 million in potential payments to GTC for meeting clinical, regulatory, and sales milestones, the companies said.

According to its website, Ovation is headquartered in Illinois.
(By Chris Reidy, Globe staff)